Top Markets
#1 Helium Helium +61.05%
#2 Seeker Seeker +36.78%
#3 Pons Pons +29.11%
#4 Zylo Ecosystem Zylo Ecosystem +27.38%
#5 TENDIES TENDIES +26.94%
#6 Bounce Bounce +21.20%
#7 UnifAI Network UnifAI Network +20.79%
#8 DAPPOS DAPPOS +14.63%
#9 Songbird Songbird +14.46%
#10 pipedog pipedog +14.20%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classement en actions #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Prix de l'action
$9.50
Dernière synchronisation: 2025-01-08
Capitalisation boursière
$819.52M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Poseida Therapeutics, Inc. (PSTX)

Catégorie

Healthcare
Ratio P/S pour Poseida Therapeutics, Inc. (PSTX)
Ratio P/S au August 2026 TTM : 14.31
Selon les derniers rapports financiers et le cours de l'action de Poseida Therapeutics, Inc., le ratio cours/ventes actuel (TTM) est 14.31. À la fin de 2022, le ratio P/S était de 2.92.
Historique du ratio P/S pour Poseida Therapeutics, Inc. de 2016 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 14.31 205.78%
2023 4.68 60.18%
2022 2.92 -99.98%
2021 13.55K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 204.33 119.21%
2016 93.21 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -28.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -29.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -79.37%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -21.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH